Shares of Advaxis, Inc. (NASDAQ:ADXS) gapped up prior to trading on Tuesday . The stock had previously closed at $0.66, but opened at $0.76. Advaxis shares last traded at $0.67, with a volume of 308,533 shares.
The business has a 50 day moving average of $0.37 and a 200 day moving average of $0.45. The company has a market cap of $45.11 million, a PE ratio of -1.39 and a beta of 3.18.
A hedge fund recently bought a new stake in Advaxis stock. ExodusPoint Capital Management LP acquired a new stake in shares of Advaxis, Inc. (NASDAQ:ADXS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 185,542 shares of the biotechnology company’s stock, valued at approximately $76,000. ExodusPoint Capital Management LP owned 0.28% of Advaxis at the end of the most recent quarter. 10.50% of the stock is currently owned by hedge funds and other institutional investors.
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer.
See Also: Shanghai Stock Exchange Composite Index
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.